Shire to pay $4.2bn for rare disease firm ViroPharma
This article was originally published in Scrip
Executive Summary
Shire has agreed to pay $4.2bn to acquire ViroPharma, which sells the orphan drug Cinryze. The prophylactic treatment is for the rare disease hereditary angioedema (HAE).
You may also be interested in...
Shire's Ornskov: The Modest Pediatrician With Fierce Corporate Ambition
Since becoming CEO of Shire in April 2013, Flemming Ornskov has overseen around $50bn in M&A deals. He steered the company through the ultimately abortive takeover by AbbVie and walked away with a break fee of $1.6bn, going on to consummate instead Shire’s $32bn acquisition of Baxalta earlier this year. He spoke to Scrip about his vision and values.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.